Mark Robert Warne

Ubiquigent Ltd. develops reagents, kits, drug discovery assay development and compound profiling services to the academic and commercial life science research community worldwide. It focus; namely the ubiquitin, ubiquitin-like and integrated signalling systems. The company has established its scientific and business credentials with both academic researchers undertaking fundamental scientific discovery as well as with pharmaceutical and biotechnology company scientists undertaking ubiquitin system-focused drug discovery. Ubiquigent was founded by Jason Brown in 2009 and is headquartered in Dundee, the United Kingdom.

Optimal Medicine Ltd. offers individualized clinical decision support software for mental health disorders. The firm’s products include ADHD care, behavioral health, and rheumatoid arthritis. Its products employ clinical and genetic information about an individual patient to generate information that guides physicians on the treatment for that patient. The company was founded by Janet Munro and Robert McBurney in 2009 and is headquartered in Newcastle-upon-Tyne, the United Kingdom.

Azellon Ltd. develops stem cell therapy for the repair of avascular meniscal tears. The firm's meniscal repair technology combines bone marrow stem cells with a special membrane that helps to deliver the cells into the injured site. The company was founded by Anthony Hollander and Troels Jordansen in 2007 and is headquartered in London, the United Kingdom.

DeepMatter Group Plc is engaged in the development of a number of projects targeting new chemicals, materials, formulations, and pharmaceuticals in commercial areas. It operates through the following segments: DeepMatter and InfoChem. The DeepMatter segment owns, develops and is in the early stage of exploiting intellectual property, software, hardware and data analysis capabilities combined as a visionary, disruptive platform called DigitalGlassware, enabling step changes in productivity and discovery for scientists in the pharma and life science sectors. The InfoChem segment develops and commercialises cheminformatics software to handle, store and retrieve chemical structures and reactions for application in pharma, life sciences, and scientific publications. The company was founded by Jon-Paul Griffiths and Mark G. Moloney on June 13, 2006 and is headquartered in Glasgow, the United Kingdom.

Genomics Plc develops research and experimental development on biotechnology. It develops and applies cutting edge analysis and algorithms to database of genomic and phenotypic data to uncover the relationships between genetic variation and human disease. The company was founded by Peter Donnely, Gil McVean, Chris Spencer and Gerton Lunter on January 10, 2004 and is headquartered in Oxford, the United Kingdom.

hVIVO Ltd. engages in the provision of clinical development services with a focus on human disease models. It specializes in human challenge studies using influenza, human rhinovirus, and respiratory syncytial virus for pharmaceutical and biotech companies. The company was founded by John Sidney Oxford in 1989 and is headquartered in London, the United Kingdom.

Capsant Neurotechnologies Ltd. provided pre-clinical assay services to the drug development industry. It offered in-vitro tissue based screening technologies based on ex-vivo tissues and reaggregated 3D systems. The firm significantly reduced the costs associated with pre-clinical drug development and shortening the overall decision process in the selection of lead candidates for clinical evaluation. The company was founded by Lars Eric Sundstrom, Ashley Ker Pringle and John Edward Chad on June 21, 2002 and was headquartered in Gray's Inn, the United Kingdom.

Part of hVIVO PLC, hVIVO Services Ltd. is a British company that specializes in full-service viral challenge studies. The company is based in London, UK. The company's services include challenge models and lab services. The company was founded in 1988 by John Sidney Oxford.

Angelini Ventures SpA (Angelini Ventures) is a venture capital firm founded in 2022. The firm is headquartered in Rome, Italy.